Table 1.

Demographic, treatment and genetic characteristics of the 189 patients included in the DOMINOS pharmacogenetic substudy (continuous data are expressed as mean±sd).

Variable	Value
Age (years)	51 ± 11
Cyclosporine AUCC2* (mg* month/L)	1156 ± 275
CDEC-MPS** (mg/month)	1568 ± 195
Randomization group (number without steroids/with steroids)	94/95
BPAR yes/no	42/126
$ Diarrhea yes/no	15/174
Anemia yes/no	175/1279
Leucopenia yes/no	23/1398
Male/Female	124/65
IMPDH2 IVS7+10 T>C (rs11706052)
TT	151 (80%)
TC	36 (19%)
CC	2 (1%)
IMPDH1 C>T (rs2278923)
CC	52 (28%)
CT	97 (51%)
TT	40 (21%)
IMPDH1 C>T (rs2278924)
CC	85 (45%)
CT	84 (44%)
TT	20 (11%)
ABCC2 -24 C>T (rs717620)
CC	124 (66%)
CT	65 (34%)
ABCC2 1249 G>A (rs2273697)
GG	120 (64%)
GA	57 (30%)
AA	12 (6%)
ABCC2 3972 C>T (rs3740066)
CC	71 (38%)
CT	87 (46%)
TT	31 (16%)
ABCC2 4544 G>A (rs8187710)
GG	161 (85%)
GA	26 (14%)
AA	2 (1%)
SLCO1B3 334 T>G (rs4149117)
TT	5 (3%)
TG	45 (24%)
GG	139 (73%)
UGT1A8 518 C>G (rs1042597)
CC	111 (59%)
CG	62 (33%)
GG	16 (8%)
UGT1A9 -2152 C>T (rs17868320)
CC	177 (94%)
CT	12 (6%)
UGT1A9 -275 T>A (rs6714486)
TT	170 (90%)
TA	18 (9%)
AA	1 (1%)
UGT 2B7 -840 G>A (rs7438135)
GG	45 (24%)
GA	86 (45%)
AA	58 (31%)
CYP2C8 G>A (rs11572076)
GG	187 (99%)
GA	2 (1%)
HUS1 (rs1056663)
GG	58 (31%)
GA	91 (48%)
AA	40 (21%)
IL12A (rs568408)
GG	154 (82%)
GA	33 (17%)
AA	2 (1%)

^*(mean C2)×follow-up duration;

^**(mean EC-MPS dose)×the follow-up period duration;

^$diarrhea episodes leading to EC-MPS dose reduction or prolonged hospitalization; for BPAR and diarrhea, the first episode was taken into account, for anemia and leucopenia, the total number of events among the whole protocol visits were taken into account.